CJC-1295 vs Sermorelin: A Comparative Review for Somatotropic Axis Research

Endogenous GHRH is a 44-amino-acid peptide, but decades of work established that its N-terminal 29-residue fragment (GRF 1-29) retains essentially full biological activity at GHRH-R, a G-protein-coupled receptor (GPCR) expressed on somatotroph cells of the anterior pituitary. That fragment, synthesized and administered as its acetate salt, is what we call sermorelin.

Sermorelin's selectivity is narrow: it acts on GHRH-R and not on the GH secretagogue receptor (GHS-R, the ghrelin receptor) or somatostatin receptors. This is consequential — unlike ipamorelin or hexarelin, sermorelin does not engage the ghrelinergic axis, so experimental observations on appetite or gastric motility from GHS-R peptides do not translate.

Plasma sermorelin degrades quickly. Reported half-lives range from 2 to 12 minutes, with a typical reference value near 10 minutes. That brevity is a limitation when sustained exposure is the goal, but it is also exactly what makes sermorelin useful for modeling a brief, endogenous-like GHRH pulse.

CJC-1295 no-DAC, also called Mod GRF 1-29, is sermorelin with four point substitutions at positions 2, 8, 15, and 27. These substitutions shield the peptide from DPP-IV (dipeptidyl peptidase IV) and other plasma proteases without altering GHRH-R affinity.

The practical result is a peptide with the same receptor profile but a plasma half-life on the order of 30 minutes — roughly three times longer than sermorelin, but still short on a pharmacological scale. In preclinical models this produces a broader, longer GH secretory pulse while remaining within the pulsatile regime of physiological signaling.

For experimental designs that require multiple daily administrations, or that aim to amplify a GHRH pulse without saturating the system, modified GRF 1-29 is the intermediate tool between fleeting sermorelin and the sustained DAC version.

The DAC (Drug Affinity Complex) version adds a maleimidopropionyl group at position 30 that reacts covalently with a free cysteine on serum albumin. Albumin then acts as a carrier protein, shielding the peptide from renal filtration and enzymatic degradation.

The pharmacokinetic impact is disproportionate. While CJC-1295 no-DAC is measured in minutes, the DAC version is measured in days: published estimates place its circulating half-life at roughly 6 to 8 days. In animal models and in early human studies in healthy adults reported by Ionescu and Frohman (2006), a single administration elevated GH and IGF-1 for over a week.

A central — and often misread — finding of that work is that endogenous GH pulsatility was not abolished. Pulse frequency and amplitude were preserved, while basal (trough) GH levels rose roughly 7.5-fold and mean GH rose about 46%. Continuous receptor stimulation did not flatten the pulsatile rhythm, suggesting the rhythm is dictated by hypothalamic oscillators (somatostatin) rather than by GHRH availability.

This distinction matters because it separates GHRH analogs from exogenous recombinant GH. Administration of recombinant GH suppresses the endogenous somatotropic axis and eliminates physiological pulsatility. GHRH analogs act upstream: they depend on somatotroph GH stores and on permissive somatostatin tone. The system retains its negative feedback.

For the investigator, this means sermorelin, CJC-1295 no-DAC, and CJC-1295 with DAC are tools to study how the axis responds to different GHRH exposure profiles, not substitutes for GH. Sermorelin is useful for short pulses; no-DAC for amplified pulses; DAC for chronic adaptation and sustained hepatic IGF-1 output.

Three practical considerations dominate current experimental design. First: equipotent dosing across these three compounds does not reduce to molar equivalence, because integrated areas under the curve differ drastically. Head-to-head comparisons must adjust for integrated exposure, not nominal dose.

Second: the somatostatin state of the model is critical. In high-somatostatin states (stress, late fasting, advanced age in some models) the response to GHRH is blunted, and all three compounds reflect this. Any potency comparison must control this axis.

Third: batch purity and analytical characterization are non-negotiable. The four substitutions of CJC-1295 no-DAC and the maleimide conjugation of DAC are synthesis-sensitive; poorly purified batches may contain partially degraded or unconjugated species that confound the experimental readout. HPLC (high-performance liquid chromatography) and mass spectrometry verification are the minimum standard.